[Methylation status of RARbeta gene promoter in low and high grade cerebral glioma. Comparison with normal tissue. Immuno-histochemical study of nuclear RARbeta expression in low and high grade cerebral glioma cells. Comparison with normal cells. 48 tumors]
- PMID: 16389900
- DOI: 10.1016/s0028-3770(05)83470-8
[Methylation status of RARbeta gene promoter in low and high grade cerebral glioma. Comparison with normal tissue. Immuno-histochemical study of nuclear RARbeta expression in low and high grade cerebral glioma cells. Comparison with normal cells. 48 tumors]
Abstract
Retinoic acid receptor beta (RARbeta) is a nuclear receptor often deregulated in tumors. An immunohistochemical study was conducted to examine the level of expression of this receptor in the nucleus of glial cell tumors (low and high grade glioma) as well as a study of the methylation status of the gene promoter coding this receptor on the same tumor samples. A comparison with normal tissue was done each time. 48 tumors were eligible for the study (15 glioblastomas, 20 grade III oligodendrogliomas and 13 grade II oligodendrogliomas). A constant decrease of RARbeta expression was found by comparison with normal tissue whatever the histological grade of the tumor, suggesting a deregulation of RARbeta gene expression. Methylation of RARbeta promoter gene was a rare event (12.5% of all cases), except for grade III oligodendrogliomas (20%), and is thus not a major event of this gene deregulation. Other reasons of this deregulation of RARbeta should be studied, such as loss of 3p24 heterozygoty, mRNA studies and RARbeta interactions with other retinoid receptors.
Similar articles
-
Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells.Oncogene. 2001 Oct 18;20(47):6820-7. doi: 10.1038/sj.onc.1204846. Oncogene. 2001. PMID: 11687961
-
5-Aza-2'-deoxycytidine induces retinoic acid receptor-beta(2) demethylation and growth inhibition in esophageal squamous carcinoma cells.Cancer Lett. 2005 Dec 18;230(2):271-83. doi: 10.1016/j.canlet.2005.01.012. Cancer Lett. 2005. PMID: 16297713
-
Responsiveness of stem-like human glioma cells to all-trans retinoic acid and requirement of retinoic acid receptor isotypes α, β and γ.Neuroscience. 2014 Oct 24;279:44-64. doi: 10.1016/j.neuroscience.2014.07.078. Epub 2014 Aug 27. Neuroscience. 2014. PMID: 25171789
-
O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.Neurosurgery. 2010 Dec;67(6):1681-91. doi: 10.1227/NEU.0b013e3181f743f5. Neurosurgery. 2010. PMID: 21107199 Review.
-
[Predictive molecular pathological testing in the diagnosis of high-grade tumors of glial origin].Magy Onkol. 2009 Mar;53(1):33-8. doi: 10.1556/MOnkol.53.2009.1.5. Magy Onkol. 2009. PMID: 19318324 Review. Hungarian.
Cited by
-
Choroid plexus papillomas: advances in molecular biology and understanding of tumorigenesis.Neuro Oncol. 2013 Mar;15(3):255-67. doi: 10.1093/neuonc/nos289. Epub 2012 Nov 21. Neuro Oncol. 2013. PMID: 23172371 Free PMC article. Review.
-
High incidence of MGMT and RARbeta promoter methylation in primary glioblastomas: association with histopathological characteristics, inflammatory mediators and clinical outcome.Mol Med. 2010 Jan-Feb;16(1-2):1-9. doi: 10.2119/molmed.2009.00140. Epub 2009 Oct 12. Mol Med. 2010. PMID: 19809523 Free PMC article.
-
The methylation of a panel of genes differentiates low-grade from high-grade gliomas.Tumour Biol. 2015 May;36(5):3831-41. doi: 10.1007/s13277-014-3025-3. Epub 2015 Jan 8. Tumour Biol. 2015. PMID: 25563195
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources